Market Place
Sourcing Support
Tubulis to Present at 43rd J.P. Morgan Healthcare Conference
17 Dec 2024 //
BUSINESSWIRE
Gilead taps Tubulis for solid tumor ADC development worth up to $465M
04 Dec 2024 //
PRESS RELEASE
Fierce Biotech Names Tubulis a "Fierce 15" Biotech Company of 2024
05 Aug 2024 //
BUSINESSWIRE
Tubulis Receives FDA Fast Track for TUB-040 in Ovarian Cancer
27 Jun 2024 //
BUSINESSWIRE
Tubulis Starts Phase I/IIa Trial Of TUB-040 In Ovarian And Lung Cancer
20 Jun 2024 //
BUSINESSWIRE
Tubulis rides wave of ADC interest to $138M financing round
14 Mar 2024 //
FIERCE BIOTECH
Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates
05 Mar 2024 //
BUSINESSWIRE
Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup
20 Apr 2023 //
ENDPTS
Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer
16 Feb 2023 //
BUSINESSWIRE
Tubulis Closes €60 Million Series B Financing
03 May 2022 //
BUSINESSWIRE
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead
20 Apr 2021 //
BUSINESSWIRE
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA
02 Dec 2020 //
PRNEWSWIRE
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA
01 Dec 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.